Page last updated: 2024-12-05

nitrofen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nitrofen: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15787
CHEMBL ID561004
CHEBI ID7590
SCHEMBL ID38981
MeSH IDM0050498

Synonyms (103)

Synonym
nitrofen (nip)
nitrahen
BIDD:ER0399
2,4-dichlorphenyl-4-nitrophenylaether
n71uyg034a ,
unii-n71uyg034a
nitrofene
AKOS005442931
2,4-dichloro-1-[(4-nitrophenyl)oxy]benzene
benzene, 2,4-dichloro-1-(4-nitrophenoxy)-
ether, 2,4-dichlorophenyl p-nitrophenyl
OPREA1_309813
nitrafen
tok e-25
2',4'-dichloro-4-nitrodiphenyl ether
nci-c00420
2,4-dechlorophenyl p-nitrophenyl ether
2,4-dichlorphenyl-4-nitrophenylaether [german]
einecs 217-406-0
2,4-dichloro-1-(4-nitrophenoxy)benzene
caswell no. 323d
trizilin 25
tok-2
niclofen
nitrofen [bsi:iso]
ccris 444
hsdb 1578
2,4-dichlorophenyl p-nitrophenyl ether
mezotox
trizilin
TOK ,
tok wp-50
nitrofen, technical-grade
tok e 40
nitrofene [french]
tokkorn
4'-nitro-2,4-dichlorodiphenyl ether
tok e
brn 1887356
nitrochlor
2,4-dichlorophenyl 4-nitrophenyl ether
2,4-dichloro-4'-nitrodiphenyl ether
nitraphen
2,4-dichloro-4'-nitrophenyl ether
4-(2,4-dichlorophenoxy)nitrobenzene
fw 925
preparation 125
epa pesticide chemical code 038201
nitrofene [iso-french]
2,4-dichlorophenyl-p-nitro phenyl ether
2',4'-dichloro-4-nitrobiphenyl ether
nitrofen (technical grade)
4-nitro-2',4'-dichlorophenyl ether
STK365913
1836-75-5
nitrofen
NCGC00163983-01
MAYBRIDGE1_005949
HMS558G09
CHEMBL561004
L000684
2,4-dichloro-(4-nitrophenoxy)-benzene;2,4-dichloro-1-(4-nitrophenoxy)-benzen;2,4-dichloro-4-nitrophenylether
2,4-dechlorophenylp-nitrophenylether
A26462
NCGC00163983-02
NCGC00163983-03
tox21_300276
dtxcid30970
NCGC00259987-01
tox21_202438
NCGC00253936-01
dtxsid7020970 ,
cas-1836-75-5
D3912
2,4-dichloro-4'-nitrobiphenyl ether
FT-0601537
nitrofen [iso]
nitrofen [mi]
nitrofen [hsdb]
nitrofen [iarc]
4-(2,4-dichloro-phenoxy)-1-nitrobenzene
SCHEMBL38981
CHEBI:7590
tok e 25
2,4-dichloro-1-(4-nitrophenoxy)benzene #
4-nitro-2',4'-dichlorodiphenyl ether
mfcd00128026
nitrofen, pestanal(r), analytical standard
nitrofen, analytical standard
nitrofen 10 microg/ml in acetonitrile
nitrofen 10 microg/ml in cyclohexane
2,4-dichloro-1-(4-nitrophenoxy)-benzene
J-011770
1-(2,4-dichlorophenoxy)-4-nitrobenzene
Q414023
F19185
DS-12551
CS-0013943
mezotox; nip; niclofen; nitrochlo
HY-B1877
4-nitro-2`,4`-dichloro-diphenyl ether
BAA83675
AKOS040757086

Research Excerpts

Overview

Nitrofen is a diphenyl ether that induces congenital diaphragmatic hernia (CDH) in rodents. The molecular etiology of these defects are poorly characterized. Nitrofen might be activated to a mutagen via reduction to the corresponding hydroxylamine.

ExcerptReferenceRelevance
"Nitrofen is a diphenyl ether that induces congenital diaphragmatic hernia (CDH) in rodents. "( Nitrofen induces apoptosis independently of retinaldehyde dehydrogenase (RALDH) inhibition.
Cavicchio, AJ; Kinane, TB; Kling, DE; Newburg, DS; Schnitzer, JJ; Sollinger, CA, 2010
)
3.25
"Nitrofen is a nitroarene and as such might be activated to a mutagen via reduction to the corresponding hydroxylamine and subsequent formation of a reactive acetic or sulfuric acid ester."( Use of genetically manipulated Salmonella typhimurium strains to evaluate the role of sulfotransferases and acetyltransferases in nitrofen mutagenicity.
Glatt, H; Meinl, W, 2004
)
1.25
"Nitrofen is a diphenyl ether herbicide that produces a spectrum of fetal abnormalities in rodents. "( Nitrofen induces a redox-dependent apoptosis associated with increased p38 activity in P19 teratocarcinoma cells.
Aidlen, JT; Donahoe, PK; Fisher, JC; Kinane, TB; Kling, DE; Schnitzer, JJ, 2005
)
3.21
"Nitrofen is a diphenyl ether that induces a spectrum of birth defects subsequent to administration to pregnant rodents, in which the molecular etiology of these defects are poorly characterized. "( Retinoic acid-mediated differentiation protects against nitrofen-induced apoptosis.
Aidlen, JT; Donahoe, PK; Kinane, TB; Kling, DE; Nazarey, PP; Schnitzer, JJ, 2007
)
2.03
"Nitrofen is a herbicide with potent teratogenic activity in rodent species. "( Teratogenicity of nitrofen (2,4-dichloro-4'-nitrodiphenyl ether) and its effects on thyroid function in the rat.
Baldwin, DM; Brown, T; Manson, JM, 1984
)
2.04

Effects

The nitrofen model has been widely used to investigate the pathogenesis of hypoplastic lungs associated with CDH. Nitrofen has been banned in Taiwan since January 1, 1983 due to its tetrogenicity.

ExcerptReferenceRelevance
"The nitrofen model has been widely used to investigate the pathogenesis of hypoplastic lungs associated with CDH."( Downregulation of p300 gene expression in airway mesenchyme of nitrofen-induced hypoplastic lungs.
Friedmacher, F; Fujiwara, N; Hofmann, A; Puri, P; Takahashi, H; Takahashi, T, 2014
)
1.12
"Nitrofen has been banned in Taiwan since January 1, 1983 due to its tetrogenicity. "( Fatal poisoning by butachlor and chlornitrofen ingested from a bottle marked as nitrofen.
Hung, DZ; Li, HP; Lin, TJ; Wong, SS; Yang, DY, 2001
)
2.02

Treatment

Both nitrofen and SU-5416 treatment increased apoptosis in the mesenchyme of fetal lung explants. Nitrofen treatment led to decreased plasma T3 and T4 levels without TSH changes. Nitrfen-treated lungs exhibited an increased number of proliferating Sox9-positive distal epithelial progenitor cells.

ExcerptReferenceRelevance
"Nitrofen-treated lungs exhibited an increased number of proliferating Sox9-positive distal epithelial progenitor cells, which were decreased and normalized by treatment with carbachol."( Defective parasympathetic innervation is associated with airway branching abnormalities in experimental CDH.
Gittes, GK; Potoka, DA; Rhodes, J; Saxena, D; Zhang, G, 2015
)
1.14
"Nitrofen treatment of these explants also showed profound lipid redistribution, primarily to phagocytes."( Nitrofen induces apoptosis independently of retinaldehyde dehydrogenase (RALDH) inhibition.
Cavicchio, AJ; Kinane, TB; Kling, DE; Newburg, DS; Schnitzer, JJ; Sollinger, CA, 2010
)
2.52
"Nitrofen treatment was associated with increased p38 MAP kinase activity, though pretreatment of cells with multiple p38 inhibitors did not affect nitrofen-mediated caspase-3 cleavage, suggesting caspase-3 cleavage is p38-independent."( Nitrofen induces a redox-dependent apoptosis associated with increased p38 activity in P19 teratocarcinoma cells.
Aidlen, JT; Donahoe, PK; Fisher, JC; Kinane, TB; Kling, DE; Schnitzer, JJ, 2005
)
2.49
"Both nitrofen and SU-5416 treatment increased apoptosis in the mesenchyme of fetal lung explants."( Impaired VEGF and nitric oxide signaling after nitrofen exposure in rat fetal lung explants.
Abman, SH; Balasubramaniam, V; Kunig, AM; Muehlethaler, V; Seedorf, G, 2008
)
1.06
"Nitrofentreated animals without CDH had intermediate patterns."( Lung growth and maturation in the rat model of experimentally induced congenital diaphragmatic hernia.
Aldazabal, P; Alfonso, LF; Lopez de Torre, B; Tovar, JA; Vilanova, J, 1993
)
1.01
"Nitrofen treatment led to decreased plasma T3 and T4 levels without TSH changes."( Thyroid hormones in the pathogenesis of lung hypoplasia and immaturity induced in fetal rats by prenatal exposure to nitrofen.
Alfonso, LF; Alvarez, FJ; Arnaiz, A; Diez-Pardo, JA; Morreale de Escobar, G; Qi, B; Tovar, JA; Valls-i-Soler, A, 1997
)
1.23
"In nitrofen-treated fetuses, the concentration of disat-PC in the lungs was lower than those in control fetuses, and surfactant apoprotein SP-A was similarly reduced in nitrofen-treated fetuses."( Impaired spreading of surfactant phospholipids in the lungs of newborn rats with pulmonary hypoplasia as a model of congenital diaphragmatic hernia induced by nitrofen.
Hashizume, K; Iwamori, M; Utsuki, T, 2001
)
1.02

Bioavailability

ExcerptReferenceRelevance
" By assessing the type of bonding involved between pesticide and plants or soil, some assessment of the bioavailability of these bound residues to the environment can be made."( Incorporation of foreign compound metabolites into plant and soil constituents.
Adler, IR; Boka, G; Honeycutt, RC; Secrest, WL; Simoneaux, BJ; Sumner, DD,
)
0.13
" Cav-1 deficiency leads to increased bioavailability of NO, which has been linked to increased nitrosative stress."( Imbalance of caveolin-1 and eNOS expression in the pulmonary vasculature of experimental diaphragmatic hernia.
Duess, JW; Friedmacher, F; Gosemann, JH; Hofmann, A; Puri, P; Takahashi, T, 2014
)
0.4

Dosage Studied

Time mated Sprague Dawley rats were dosed with nitrofen at day 9. It was concluded that effects of maternal malnutrition were extensive.

ExcerptRelevanceReference
"Beginning the day after hatching, American kestrel (Falco sparverius) nestlings were orally dosed for 10 consecutive days with 5 microliters/g of corn oil (controls) or one of the diphenyl ether herbicides (nitrofen, bifenox, or oxyfluorfen) at concentrations of 10, 50, 250, or 500 mg/kg in corn oil."( Developmental toxicity of diphenyl ether herbicides in nestling American kestrels.
Bunck, CM; Hoffman, DJ; LeCaptain, LJ; Rattner, BA; Spann, JW, 1991
)
0.47
"The Rai and Van Ryzin dose-response model proposed for teratology experiments has been characterized for its appropriateness and applicability in modeling the dichotomous response data from developmental toxicity studies."( Characterization of a developmental toxicity dose-response model.
Faustman, EM; Kimmel, CA; Smith, WP; Wellington, DG, 1989
)
0.28
" It is concluded that effects of maternal malnutrition were extensive, but that nitrofen exposure, at this dosage level, is not likely to contribute to the postnatal fetal mortality rate in either adequately nourished or malnourished rats."( Effects on the fetal rat intestine of maternal malnutrition and exposure to nitrofen (2,4-dichlorophenyl-p-nitrophenyl ether).
Hoogenboom, ER; Kavlock, RJ; Mahboob, S; Zeman, FJ, 1986
)
0.73
" These anomalies were produced by both oral and dermal doses, but did not occur in the rabbit or when dosing was restricted to the male parent only."( Nitrofen: a review and perspective.
Hayes, AW; Hurt, SS; Smith, JM, 1983
)
1.71
" At 2500 ppm, body weights of paternal animals were reduced throughout the dosing period."( The effect of nitrofen [4-(2,4-dichlorophenoxy)nitrobenzene] on the reproductive performance of male rats.
Burke, SS; Chan, PK; Harris, JC; Hayes, AW; O'Hara, GP; Smith, JM, 1983
)
0.63
" The peak concentration of radioactivity occurred 7-9 h after dosing and the half-life of the label in maternal blood was approximately 8 days."( Distribution and metabolism of the teratogen nitrofen (2,4-dichloro-4'-nitro diphenyl ether) in pregnant rats.
Costlow, RD; Manson, JM, 1983
)
0.53
" Diaphragmatic defects occurred in a dose-response fashion: 0% (0/48) control or sham-fed, 5% (5/104) in the low-dose group, and 25% (19/75) in the high-dose group."( Nitrofen-induced congenital diaphragmatic defects in CD1 mice.
Benjamin, DR; Siebert, JR; Wickman, DS, 1993
)
1.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitorAn EC 1.3.3.* (oxidoreductase acting on donor CH-CH group with oxygen as acceptor) inhibitor that interferes with the action of protoporphyrinogen oxidase (EC 1.3.3.4).
herbicideA substance used to destroy plant pests.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency100.83500.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency63.62230.002541.796015,848.9004AID1347395
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency55.25043.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency34.55110.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency56.21790.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency27.93030.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency51.25280.000657.913322,387.1992AID1259377; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency33.26030.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency12.56100.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency27.44490.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.77070.000817.505159.3239AID1159527; AID1159531; AID588544
farnesoid X nuclear receptorHomo sapiens (human)Potency17.78280.375827.485161.6524AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency41.47180.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency49.37380.000229.305416,493.5996AID1259244; AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency68.58960.000723.06741,258.9301AID743085
thyroid stimulating hormone receptorHomo sapiens (human)Potency66.05580.001628.015177.1139AID1259385; AID1259395
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency31.89680.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency127.48900.039147.5451146.8240AID1224845
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency45.66480.000627.21521,122.0200AID651741; AID720636; AID743202
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency43.49730.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency43.49730.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (399)

TimeframeStudies, This Drug (%)All Drugs %
pre-199044 (11.03)18.7374
1990's58 (14.54)18.2507
2000's138 (34.59)29.6817
2010's136 (34.09)24.3611
2020's23 (5.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.37 (24.57)
Research Supply Index6.02 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index104.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.24%)5.53%
Reviews8 (1.95%)6.00%
Case Studies3 (0.73%)4.05%
Observational0 (0.00%)0.25%
Other398 (97.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]